美康生物
(300439)
| 流通市值：30.14亿 | | | 总市值：39.66亿 |
| 流通股本：2.92亿 | | | 总股本：3.84亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 374,030,860.65 | 1,742,424,499.51 | 1,406,709,821.37 | 949,125,024.71 |
| 营业收入 | 374,030,860.65 | 1,742,424,499.51 | 1,406,709,821.37 | 949,125,024.71 |
| 二、营业总成本 | 350,212,593.71 | 1,525,930,374.42 | 1,191,514,043.79 | 783,304,290.35 |
| 营业成本 | 225,347,929.5 | 966,144,069.16 | 762,448,197.92 | 507,936,055.55 |
| 税金及附加 | 4,145,273.19 | 15,282,849.54 | 13,184,164.56 | 7,961,419.08 |
| 销售费用 | 52,108,293.45 | 237,206,923.84 | 189,442,033.35 | 118,840,193.78 |
| 管理费用 | 33,660,531.64 | 165,900,996.86 | 118,152,270.43 | 77,100,369.36 |
| 研发费用 | 35,830,195.42 | 146,467,706.46 | 114,751,323.89 | 76,369,719.17 |
| 财务费用 | -879,629.49 | -5,072,171.44 | -6,463,946.36 | -4,903,466.59 |
| 其中:利息费用 | 377,141.43 | 2,523,612.15 | 1,514,399 | 1,277,023.67 |
| 其中:利息收入 | 1,337,828.91 | 10,351,098.81 | 7,851,136.02 | 6,333,311.8 |
| 加:公允价值变动收益 | 605,752.74 | 81,517.67 | 380,288.89 | 213,263.89 |
| 加:投资收益 | -2,738,528.61 | 14,458,479.33 | 14,474,621.09 | 8,533,476.56 |
| 资产处置收益 | 10,588.74 | -665,892.86 | 8,580.98 | 8,580.98 |
| 资产减值损失(新) | -431,720.71 | -17,776,445.45 | -1,601,744.14 | -1,465,535.74 |
| 信用减值损失(新) | 1,573,699.02 | 20,768,222.16 | 4,900,206.55 | 1,950,491.29 |
| 其他收益 | 11,172,090.16 | 34,170,313.99 | 16,854,995.32 | 12,104,348.05 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 34,010,148.28 | 267,530,319.93 | 250,212,726.27 | 187,165,359.39 |
| 加:营业外收入 | 8,137.54 | 21,893,787.72 | 9,159,902.01 | 9,005,869.02 |
| 减:营业外支出 | 954,470.67 | 7,064,112.18 | 4,392,548.76 | 1,461,982.94 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 33,063,815.15 | 282,359,995.47 | 254,980,079.52 | 194,709,245.47 |
| 减:所得税费用 | 3,284,761.12 | 19,685,270.75 | 31,650,540.8 | 16,383,586.45 |
| 六、净利润 | 29,779,054.03 | 262,674,724.72 | 223,329,538.72 | 178,325,659.02 |
| 持续经营净利润 | 29,779,054.03 | 262,674,724.72 | 223,329,538.72 | 178,325,659.02 |
| 归属于母公司股东的净利润 | 30,397,722.74 | 257,997,230.71 | 224,363,611.78 | 178,463,238.99 |
| 少数股东损益 | -618,668.71 | 4,677,494.01 | -1,034,073.06 | -137,579.97 |
| (一)基本每股收益 | 0.08 | 0.67 | 0.58 | 0.46 |
| (二)稀释每股收益 | 0.08 | 0.67 | 0.58 | 0.46 |
| 八、其他综合收益 | -1,157,261.16 | 10,988,800.8 | -4,248,904.58 | -5,244,221.58 |
| 归属于母公司股东的其他综合收益 | -890,345.17 | 12,198,718.21 | -3,242,176.08 | -3,641,276.68 |
| 九、综合收益总额 | 28,621,792.87 | 273,663,525.52 | 219,080,634.14 | 173,081,437.44 |
| 归属于母公司股东的综合收益总额 | 29,507,377.57 | 270,195,948.92 | 221,121,435.7 | 174,821,962.31 |
| 归属于少数股东的综合收益总额 | -885,584.7 | 3,467,576.6 | -2,040,801.56 | -1,740,524.87 |
| 公告日期 | 2025-04-26 | 2025-04-19 | 2024-10-26 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |